Literature DB >> 26319148

Routine disc diffusion antimicrobial susceptibility testing of Clostridium difficile and association with PCR ribotype 027.

H M Holt1, T K Danielsen1, U S Justesen2.   

Abstract

Reduced susceptibility to metronidazole and vancomycin in Clostridium difficile has been reported, which emphasises the need for simple antimicrobial susceptibility testing methods. The aim of this study was to apply a published disc diffusion method and zone diameter breakpoint correlates to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) epidemiological minimum inhibitory concentration (MIC) cut-off values in a routine setting. Metronidazole and vancomycin zone diameters from 2702 isolates were recorded. Fifteen isolates had a metronidazole zone diameter below the published breakpoint (<23 mm) and five isolates had a vancomycin zone diameter below the published breakpoint (<19 mm), most of which were polymerase chain reaction (PCR) ribotype 027. The total number of PCR ribotype 027 was 29 (1.1 %). Overall, C. difficile PCR ribotype 027 isolates had smaller zone diameters than non-027 isolates. The disc diffusion method is very simple and inexpensive, and the published zone diameter breakpoints will detect C. difficile isolates with reduced susceptibility to metronidazole and vancomycin.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26319148     DOI: 10.1007/s10096-015-2475-x

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  11 in total

1.  Reduced susceptibility of Clostridium difficile to metronidazole.

Authors:  J S Brazier; W Fawley; J Freeman; M H Wilcox
Journal:  J Antimicrob Chemother       Date:  2001-11       Impact factor: 5.790

2.  A multiplex, internally controlled real-time PCR assay for detection of toxigenic Clostridium difficile and identification of hypervirulent strain 027/ST-1.

Authors:  A M Hoegh; J B Nielsen; A Lester; A Friis-Møller; K Schønning
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-09-22       Impact factor: 3.267

3.  European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection.

Authors:  S B Debast; M P Bauer; E J Kuijper
Journal:  Clin Microbiol Infect       Date:  2014-03       Impact factor: 8.067

4.  Evaluation of a rapid molecular screening approach for the detection of toxigenic Clostridium difficile in general and subsequent identification of the tcdC Δ117 mutation in human stools.

Authors:  R F de Boer; J J Wijma; T Schuurman; J Moedt; B G Dijk-Alberts; A Ott; A M D Kooistra-Smid; Y T H P van Duynhoven
Journal:  J Microbiol Methods       Date:  2010-07-30       Impact factor: 2.363

5.  Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest.

Authors:  S S Wong; P C Woo; W K Luk; K Y Yuen
Journal:  Diagn Microbiol Infect Dis       Date:  1999-05       Impact factor: 2.803

6.  Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes.

Authors:  J Freeman; J Vernon; K Morris; S Nicholson; S Todhunter; C Longshaw; M H Wilcox
Journal:  Clin Microbiol Infect       Date:  2014-10-13       Impact factor: 8.067

7.  Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.

Authors:  T Peláez; L Alcalá; R Alonso; M Rodríguez-Créixems; J M García-Lechuz; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

8.  Antimicrobial susceptibility testing of Clostridium difficile using EUCAST epidemiological cut-off values and disk diffusion correlates.

Authors:  L T Erikstrup; T K L Danielsen; V Hall; K E P Olsen; B Kristensen; G Kahlmeter; K Fuursted; U S Justesen
Journal:  Clin Microbiol Infect       Date:  2012-06-04       Impact factor: 8.067

9.  Emergence of reduced susceptibility to metronidazole in Clostridium difficile.

Authors:  Simon D Baines; Rachael O'Connor; Jane Freeman; Warren N Fawley; Celine Harmanus; Paola Mastrantonio; Ed J Kuijper; Mark H Wilcox
Journal:  J Antimicrob Chemother       Date:  2008-08-07       Impact factor: 5.790

Review 10.  Consequences of Clostridium difficile infection: understanding the healthcare burden.

Authors:  E Bouza
Journal:  Clin Microbiol Infect       Date:  2012-12       Impact factor: 8.067

View more
  1 in total

Review 1.  Update on Antimicrobial Resistance in Clostridium difficile: Resistance Mechanisms and Antimicrobial Susceptibility Testing.

Authors:  Zhong Peng; Dazhi Jin; Hyeun Bum Kim; Charles W Stratton; Bin Wu; Yi-Wei Tang; Xingmin Sun
Journal:  J Clin Microbiol       Date:  2017-04-12       Impact factor: 5.948

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.